6505--Buprenorphine Pre-solicitation notice

Solicitation / RFP / RFQ

This solicitation seeks proposals for the supply of Buprenorphine HCl 2mg/Naloxone HCl 0.5mg Tabs (Sublingual, 30/Bottle) and Buprenorphine HCl 8mg/Naloxone HCl 2mg Tabs (Sublingual, 30/Bottle). The contract will establish national contract prices for these products, to be distributed through the VA and DoD Pharmaceutical Prime Vendor (PPV) Programs. The objective is to ensure product availability and consistency nationwide with volume-based pricing.

• Products: Buprenorphine HCl 2mg/Naloxone HCl 0.5mg Tabs (Sublingual, 30/Bottle) and Buprenorphine HCl 8mg/Naloxone HCl 2mg Tabs (Sublingual, 30/Bottle).

• Packaging: Unit of use bottles (30 count) must have safety caps, a minimum 120cc volume, cylindrical body, 5.75" circumference, and fit a 5.25" x 2" label with 0.5" additional space.

• Technical: Products must meet specific packaging and barcoding (GS1-128 or HIBCC HIBC) requirements. Compliance with FDA cGMP standards is mandatory.

• DSCSA: Compliance with Drug Supply Chain Security Act (DSCSA) requirements, including serialized transaction information and statements using GS1 EPCIS files.

• Product Registration: Offerors must submit product information, including NDC, for registration with FDA, First Databank, Medispan, and Cerner Multum within 5 days of award.

• Manufacturer Requirements: Offerors not manufacturing the product must submit a Letter of Commitment from the manufacturer. The same manufacturer (NDA/ANDA/BLA) must be maintained throughout the contract period unless approved otherwise.

• Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements contract.

• Ordering Period: Base year plus four one-year option periods.

• Implementation Period: Maximum of 60 days from contract award.

• Cost Recovery Fee: 0.5% Cost Recovery Fee is embedded in all offered prices.

• Submission Method: Proposals accepted via email in Microsoft Word or PDF format to Amber.Zavala@va.gov and Diana.Martinez1@va.gov, with a scanned SF-1449. Faxed proposals are not accepted.

• Pricing: Offerors must submit prices for line items 1 and 2 for the base year and all four option years. Prices must not exceed two decimal places.

• Evaluation: Award will be made to the responsible offeror with the lowest price technically acceptable offer. Technical acceptability includes meeting product descriptions, NDC uniqueness, FDA approval, FDA cGMP compliance, and manufacturing facility clearance.

• Deadline: Offerors must hold prices firm for 120 calendar days from the receipt date.

• Subcontracting Plan: Non-small business concerns must submit an approved subcontracting plan for contracts over $750,000.

• Covered Drugs: Offers of covered drugs must have an executed Master Agreement (MA) and Pharmaceutical Pricing Agreement (PPA) with VA FSS, and the proposed products must be on the Offeror’s FSS contract or interim agreement.

• Offerors must maintain current and accurate SAM registration.

• Proposals failing to include pricing for all line items and years may be rejected.

• The document references several attachments (A, B, C, D) detailing PPV contractors, estimated requirements, and subcontracting plan templates.

Solicitation / RFP / RFQ

This is a pre-solicitation notice for an unrestricted procurement of Buprenorphine HCL/Naloxone HCL Tablets. The Department of Veterans Affairs (VA) National Acquisition Center intends to issue a Request for Proposal (RFP) for an uninterrupted source of supply for these items, to be distributed through the VA's and Department of Defense's (DOD) Pharmaceutical Prime Vendor Programs. The procurement also serves the Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS).

• Buprenorphine HCL 2mg/Naloxone HCL 0.5mg Tablets, Sublingual (30 count bottles)

• Buprenorphine HCL 8mg/Naloxone HCL 2mg Tablets, Sublingual (30 count bottles)

• Offerors must state the exact name (as it appears on the label) by which the drug will be supplied.

• Offerors must have a unique NDC number for the drug.

• Glass bottles are not acceptable.

• Contract type: Not specified, but will be in commercial item format per FAR Part 12.

• Period of Performance: One year plus four pre-priced one-year option periods.

• The solicitation (RFP # 36E79726R0004) will be issued electronically on or about January 5, 2026.

• Tentative closing date for proposals: January 19, 2026, 2:30 pm Central Time, Chicago, USA.

• All future amendments and documents will be available at http://www.sam.gov.

• No paper copies will be available or accepted via telephone requests.

• Interested offerors should continuously check the SAM.gov URL for updates.

• All responsible sources may submit an offer.

• Unrestricted procurement.

• NAICS Code: 325412

• Estimated Annual Requirements:

  • Buprenorphine HCL 2mg/Naloxone HCL 0.5mg Tab, Sublingual (30 count): 171,239 bottles
  • Buprenorphine HCL 8mg/Naloxone HCL 2mg Tab, Sublingual (30 count): 251,144 bottles

• Point of Contact: Amber Zavala (Amber.Zavala@va.gov, (708) 786-5245)